The Alzheimer Disease Protective Mutation A2T Modulates Kinetic and Thermodynamic Properties of Amyloid-β (Aβ) Aggregation
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Missense mutations in alanine 673 of the amyloid precursor protein (APP), which corresponds to the second alanine of the amyloid β (Aβ) sequence, have dramatic impact on the risk for Alzheimer disease; A2V is causative, and A2T is protective. Assuming a crucial role of amyloid-Aβ in neurodegeneration, we hypothesized that both A2V and A2T mutations cause distinct changes in Aβ properties that may at least partially explain these completely different phenotypes. Using human APP-overexpressing primary neurons, we observed significantly decreased Aβ production in the A2T mutant along with an enhanced Aβ generation in the A2V mutant confirming earlier data from non-neuronal cell lines. More importantly, thioflavin T fluorescence assays revealed that the mutations, while having little effect on Aβ42 peptide aggregation, dramatically change the properties of the Aβ40 pool with A2V accelerating and A2T delaying aggregation of the Aβ peptides. In line with the kinetic data, Aβ A2T demonstrated an increase in the solubility at equilibrium, an effect that was also observed in all mixtures of the A2T mutant with the wild type Aβ40. We propose that in addition to the reduced β-secretase cleavage of APP, the impaired propensity to aggregate may be part of the protective effect conferred by A2T substitution. The interpretation of the protective effect of this mutation is thus much more complicated than proposed previously.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064 · cited 1×
“A11 reactivity of oligomeric species is often regarded as a correlate of their toxic potencies (35, 36).”
BackgroundKarran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · cited 1×
“This reinforces the amyloid hypothesis of AD, which suggests that abnormal amyloid generation is a triggering, initiating, or driving event in the disease cascade (1).”
BackgroundSelf-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962 · cited 2×
“Compelling evidence, however, indicates that such aggregated A peptides can directly affect memory formation, synaptic transmission, and neuron viability (18, 20).”
BackgroundSelf-citationAβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938 · cited 1×
“Compelling evidence, however, indicates that such aggregated A peptides can directly affect memory formation, synaptic transmission, and neuron viability (18, 20).”
BackgroundA mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · cited 9×
“These authors provided evidence that the Ala-to-Thr substitution decreased -secretase cleavage of APP and therefore the generation of A peptide with about 40% in a cell line (21).”
BackgroundResultInfluentialMullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., & Lannfelt, L. (1992) · Nature Genetics · doi:10.1038/ng0892-345 · Cited by 1,513 · cited 1×
“Indeed, only the Swedish double mutation KM670/671NL (4), the recessive A2V mutation (5), and the putative AD mutation E11K (6) (Fig.”
BackgroundOligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability
Dahlgren, K. N., Manelli, A. M., Stine, W. B., Baker, L. K., Krafft, G. A., & LaDu, M. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201750200 · Cited by 1,452
Kayed, R., Head, E., Sarsoza, F., Saing, T., Cotman, C. W., Necula, M., Margol, L., Wu, J., Breydo, L., Thompson, J. L., et al. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-18 · Cited by 773
Cited by
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
“Moreover, this benefit may be compounded, because the ª 2016 The Authors EMBO Molecular Medicine Vol 8 | No 6 | 2016 mutant Ab peptide that is generated has altered aggregation properties (Benilova et al, 2014; Maloney et al, 2014; Zheng et al, 2015).”
BackgroundAPP mouse models for Alzheimer’s disease preclinical studies.
Sasaguri, H., Nilsson, P., Hashimoto, S., Nagata, K., Saito, T., De Strooper, B., Hardy, J., Vassar, R., Winblad, B., & Saido, T. C. (2017) · The EMBO Journal · doi:10.15252/embj.201797397 · Cited by 793
Amyloid β Protein and Alzheimer’s Disease: When Computer Simulations Complement Experimental Studies
Nasica-Labouze, J., Nguyen, P. H., Sterpone, F., Berthoumieu, O., Buchete, N.-V., Coté, S., De Simone, A., Doig, A. J., Faller, P., Garcia, A., et al. (2015) · Chemical Reviews · doi:10.1021/cr500638n · Cited by 584
Molecular dynamics simulations and novel drug discovery
Liu, X., Shi, D., Zhou, S., Liu, H., Liu, H., & Yao, X. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1403419 · Cited by 518
Kennedy, M. E., Stamford, A. W., Chen, X., Cox, K., Cumming, J. N., Dockendorf, M. F., Egan, M., Ereshefsky, L., Hodgson, R. A., Hyde, L. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9704 · Cited by 428
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
Vassar, R. (2014) · Alzheimer's Research & Therapy · doi:10.1186/s13195-014-0089-7 · Cited by 410
The amyloid cascade hypothesis: are we poised for success or failure?
Karran, E., & De Strooper, B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13632 · Cited by 402
“1) decreases both the production and aggregatory properties of Ab (Benilova et al. 2014; Maloney et al. 2014).”
BackgroundClearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes
Zuroff, L., Daley, D., Black, K. L., & Koronyo-Hamaoui, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2463-7 · Cited by 275
Actin dynamics and cofilin‐actin rods in alzheimer disease
Bamburg, J. R., & Bernstein, B. W. (2016) · Cytoskeleton · doi:10.1002/cm.21282 · Cited by 181
“Characterization of diverse Ab processing and the functional significance of the resultant products have received much attention without yielding firm conclusions as to the nature of the basic building blocks [Schilling et al., 2006; Wirths et al., 2009; Benilova et al., 2014].”
BackgroundBACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease
Barão, S., Moechars, D., Lichtenthaler, S. F., & De Strooper, B. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.01.003 · Cited by 158
Self-citationProtective genes and pathways in Alzheimer’s disease: moving towards precision interventions
Seto, M., Weiner, R. L., Dumitrescu, L., & Hohman, T. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00452-5 · Cited by 135
“A673T allele results in a suboptimal β-secretase cleavage site that reduces production of pathologic Aβ by 50% in comparison to wild-type cells and delayed Aβ aggregation [59, 60].”
BackgroundUnderstanding the roles of mutations in the amyloid precursor protein in Alzheimer disease
Hunter, S., & Brayne, C. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.218 · Cited by 94
Walter, J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.704981 · Cited by 80
“In contrast to the disease-causing mutations of APP, the preventive variant decreased the proteolytic generation of A and its propensity to aggregate (61, 62).”
Schönherr, C., Bien, J., Isbert, S., Wichert, R., Prox, J., Altmeppen, H., Kumar, S., Walter, J., Lichtenthaler, S. F., Weggen, S., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0084-5 · Cited by 76
Modulation of γ- and β-secretases as early prevention against Alzheimer's disease
Voytyuk, I., De Strooper, B., & Chávez-Gutiérrez, L. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.001 · Cited by 67
“This mutation also affects the aggregation properties of Aβ (74, 75) and induces alternative Bace1 cleavage at the β’ site in”
Liebsch, F., Kulic, L., Teunissen, C., Shobo, A., Ulku, I., Engelschalt, V., Hancock, M. A., van der Flier, W. M., Kunach, P., Rosa-Neto, P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10152-w · Cited by 68
Fu, X., Qin, T., Yu, J., Jiao, J., Ma, Z., Fu, Q., Deng, X., & Ma, S. (2019) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527318666190807160137 · Cited by 42
Alzheimer’s protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity
Limegrover, C. S., LeVine, H., Izzo, N. J., Yurko, R., Mozzoni, K., Rehak, C., Sadlek, K., Safferstein, H., & Catalano, S. M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15212 · Cited by 24
Architectonic principles of polyproline II helix bundle protein domains
Rodríguez, C. S., & Laurents, D. V. (2024) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2024.109981 · Cited by 9
Architectonic Principles of Polyproline II Helix Bundle Protein Domains
(2023) · doi:10.1101/2023.11.25.568672 · Cited by 9
Metadata
- Authors
- Benilova, I., Gallardo, R., Ungureanu, A.-A., Castillo Cano, V., Snellinx, A., Ramakers, M., Bartic, C., Rousseau, F., Schymkowitz, J., & De Strooper, B.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 289
- Issue
- 45
- Pages
- 30977-30989
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2076309706
- Cited by
- 145
- References
- 19
- FWCI
- 12.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.